Abstract

Association of Vedolizumab Level, Anti-drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases

Ungar B1, Kopylov U2, Yavzori M2, Fudim E2, Picard O2, Lahat A2, Coscas D2, Waterman M3, Haj-Natour O2, Orbach-Zingboim N2, Mao R4, Chen M4, Chowers Y3, Eliakim R2, Ben-Horin S5. Clin Gastroenterol Hepatol. 2017 Dec 6. pii: S1542-3565(17)31423-4. doi: 10.1016/j.cgh.2017.11.050. [Epub ahead of print]
 
     
Author information

1 Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Aviv. Electronic address: bellageyshis@gmail.com.

2 Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Aviv.

3 Rambam Health Care Campus, Bruce & Ruth Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa.

4 Israel, and The First Affiliated Hospital of Sun-Yatsen University, Guangzhou, China.

5 Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Aviv; Israel, and The First Affiliated Hospital of Sun-Yatsen University, Guangzhou, China. Electronic address: shomron.benhorin@gmail.com.

Abstract

BACKGROUND & AIMS: There are few data available on the real-life pharmacokinetic and pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We performed a prospective study of patients with inflammatory bowel diseases (IBD) treated with vedolizumab to determine serum drug concentrations, formation of anti-vedolizumab antibodies (AVAs), and integrin α4β7 saturation.

METHODS: We performed a prospective study of 106 patients with IBD (67 with Crohn's disease and 39 with ulcerative colitis) treated with vedolizumab from September 2014 through March 2017 at 2 tertiary medical centers in Israel. Clinical data and serum samples were collected before and during induction and maintenance therapy. Clinical remission was defined as Harvey-Bradshaw index scores below 5 or as Simple Clinical Colitis Activity Index scores of 3 or less. We measured serum levels of vedolizumab, AVAs, and markers of inflammation. Peripheral blood mononuclear cells were obtained from some patients at designated trough timepoints and CD3+ CD45RO+ T cells were isolated from 36 samples. Cells were incubated with fluorescent-conjugated vedolizumab and flow cytometry was used to quantify α4β7 integrin saturation. We also performed flow cytometry analyses of CD3+ CD45RO+ lamina propria T cells isolated from intestinal mucosa of patients without IBD (non-IBD controls, n=6), patients with IBD not treated with vedolizumab (untreated IBD controls, n=8) and patients with IBD treated with vedolizumab (n=15).

RESULTS: Clinical remission was achieved by 48/106 patients (45%) by week 6 and 50/106 patients (48%) by week 14 of treatment. The median level of vedolizumab at week 6 was higher in patients in clinical remission (40.2 μg/mL) than in patients with active disease (29.7 μg/mL; P=.05). The median serum level of vedolizumab was significantly higher in patients with normal level of c-reactive protein (21.8 μg/mL vedolizumab) vs the level in those with a high level of c-reactive protein (11.9 μg/mL vedolizumab) during maintenance treatment (P=.0006). The other clinical outcomes measured were not associated with median serum level of vedolizumab at any time point examined. AVAs were detected in 17% of patients during induction therapy and 3% of patients during maintenance therapy, but did not correlate with clinical outcomes. Flow-cytometry analysis of peripheral blood memory T cells (n=36) showed near-complete occupancy of α4β7 integrin at weeks 2 and 14 and during maintenance phase, regardless of response status or drug levels. Most intestinal CD3+CD45RO+ memory T cells of healthy and IBD controls expressed α4β7 (72%; inter-quartile range, 56%-81%). In contrast, free α4β7 was detectable on only 5.6% of intestinal memory cells (inter-quartile range, 4.4%-11.2%) (P<.0001) from vedolizumab-treated patients, regardless of response.

CONCLUSION: In a prospective study of real-life patients with IBD, we associated vedolizumab drug levels with remission and level of a marker of inflammation. Integrin α4β7 was blocked in almost all T cells from patients treated with vedolizumab, regardless of serum level of the drug or response to treatment. These findings indicate a need to explore alternative mechanisms that prevent response to vedolizumab.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.